CSPG4 and melanoma: Overall, our findings strongly support the rationale to utilize CIK as a valuable platform for CAR engineering and provide reliable translational bases to explore anti-CSPG4 CAR-based immunotherapies in clinical studies within the challenging setting of patients harboring HLA-defective melanoma who do not benefit from treatment with immune checkpoint inhibitors.